Aklief (trifarotene) / Galderma - LARVOL DELTA

A Retrospective Analysis of Adherence to Acne Treatment Guidelines (AAD 2025) - "Topical treatments (adapalene, benzoyl peroxide, tazarotene, tretinoin, trifarotene) tried within 12 months prior to antibiotics were included. This study provides an automated approach to assess adherence to acne treatment guidelines. Next steps involve educating providers on these guidelines and assessing changes in adherence."

Adherence • Retrospective data • Acne Vulgaris • Dermatology • Dermatopathology • Hidradenitis Suppurativa • Immunology • Infectious Disease • Malaria • Pneumonia • Respiratory Diseases • Rosacea

Cleanse, Treat, Moisturize, Protect (CTMP®) regimen: Enhancing skin quality and treatment outcomes in acne and sensitive skin (AAD 2025) - "Retinoids, such as adapalene, tretinoin, tazarotene, and trifarotene, are considered fundamental topical acne treatments as they target multiple disease aspects (5), and are frequently studied with regimens of cleansers, moisturizers, and protection (6-11). The review also found that combined drug treatments (e.g., topical trifarotene or other retinoids) and corrective procedures (e.g., fillers) may provide optimal treatment outcomes and satisfaction for some patients (21). Overall, the narrative review found that CTMP® may improve adherence, treatment outcomes, patient satisfaction, and overall skin quality in patients with acne and/or sensitive skin."

Clinical • Acne Vulgaris

Retinoids as Alternative Antifungal Agents Against Candida albicans: In Vitro and In Silico Evidence. (PubMed, Microorganisms) - "Here, we further investigated the possible anti-Candida potential of trifarotene and tazarotene, which are the other two molecules belonging to the retinoid family, compared to ATRA. In silico studies suggest that all three retinoids may exert antifungal activity through their molecular interactions with the heat shock protein (Hsp) 90 and 14α-demethylase of C. albicans. Moreover, interactions between retinoids and ergosterol have been observed, suggesting that those compounds have great potential against C. albicans infections."

Journal • Preclinical • Candidiasis • Dermatology • Infectious Disease

Recommendations to Improve Outcomes in Acne and Acne Sequelae: A Focus on Trifarotene and Other Retinoids. (PubMed, Dermatol Ther (Heidelb)) - "Adapalene, tretinoin and tazarotene have demonstrated efficacy in reducing acne and acne sequelae in several studies. Finally, management of acne and acne sequelae should include maintenance therapy with topical retinoids. This article supports the American Academy of Dermatology's call for acne sequelae treatment guidance and emphasizes the need for continued research to optimize patient care."

Journal • Acne Vulgaris • Dermatology

A Real-World Approach to Trifarotene Treatment in Patients with Acne and Acne Sequelae Based on the Experience of the Italian Acne Board. (PubMed, Dermatol Ther (Heidelb)) - "Owing to its long-term efficacy and tolerability, trifarotene is also a good option as a maintenance treatment. As with other topical retinoids, patients undergoing trifarotene therapy should be given advice on how to minimise local irritation when starting treatment."

Journal • Real-world evidence • Acne Vulgaris • Dermatology

A Study Comparing Trifarotene Cream 0.005% to AKLIEF® CREAM (US REFERENCE LISTED DRUG), AKLIEF™ CREAM (CANADIAN REFERENCE PRODUCT) in the Treatment of Acne Vulgaris (clinicaltrials.gov) - P1 | N=1000 | Completed | Sponsor: Taro Pharmaceuticals USA

New P1 trial • Acne Vulgaris • Dermatology

A Multimodal Approach to Acne-Induced Post-Inflammatory Hyperpigmentation: Trifarotene as a Long-Term Intervention. (PubMed, Skin Therapy Lett) - "Trifarotene, a novel fourth generation retinoid selective for retinoid acid receptor gamma, is approved for the management of moderate-to-severe facial and truncal acne, with recent data supporting its efficacy in acne-induced hyperpigmentation. The purpose of this paper is to review treatment modalities for post-inflammatory hyperpigmentation and present trifarotene as a novel, evidence-based topical option."

Journal • Review • Acne Vulgaris • Dermatology

Innovations in Acne. (PubMed, Dermatol Clin) - "The mechanisms of action, pivotal trial data, and potential role in clinical practice are reviewed for emerging therapies such as 1726 nm laser, sarecycline, clascoterone, trifarotene, minocycline foam, and fixed-dose combination topicals. The clinical pipeline is also summarized. In addition, opportunities to improve the patient experience with spironolactone and isotretinoin are discussed."

Journal • Review • Acne Vulgaris • Dermatology

One Acne™: a holistic management approach to improve overall skin quality and treatment outcomes in acne with or without sensitive skin. (PubMed, Int J Dermatol) - "Tretinoin, trifarotene, adapalene, and tazarotene have all been assessed in clinical studies for managing acne-associated scarring, with varying success, with the latter three reported to improve skin quality. This narrative review highlights that comprehensive skincare regimens should be used throughout acne patients' journeys to reduce treatment-related irritation, improve treatment outcomes, adherence, and satisfaction, and enhance overall skin quality. Patients with sensitive skin should choose tailored skincare products to maintain skin barrier integrity and restore skin function."

Journal • Review • Acne Vulgaris • Dermatology

An update on the pharmacological management of acne vulgaris: the state of the art. (PubMed, Expert Opin Pharmacother) - "Topical therapies such as topical retinoids, benzoyl peroxide, azelaic acid, salicylic acid, topical antibiotics and clascoterone, as well as systemic treatments such as oral antibiotics and isotretinoin are discussed in detail. Combined oral contraceptives and spironolactone will not be discussed in this article. There is a need for a blockbuster acne drug that simultaneously targets the 4 main pathogenic factors involved in the appearance of acne lesions while presenting with minimal side effects. Until such a drug exists, combination therapy will remain the standard of treatment for most acne patients."

Journal • Review • Acne Vulgaris • Dermatology • Inflammation

Evidence for trifarotene in the management of acne and acne sequelae (EADV 2024) - "Sponsored by Galderma."

Acne Vulgaris

Hub 1.14 OneAcne: A holistic management approach to improve treatment outcomes in acne, acne sequelae and skin quality (EADV 2024) - "Furthermore, they will delve into the current understanding of the pathogenesis of acne, atrophic acne scarring and acne-induced hyperpigmentation, while also sharing data from the Phase 4 START and LEAP post hoc analyses on topical treatments with trifarotene for these conditions. Join the conversation! We encourage you to share your thoughts and ask questions in an interactive Q&A at the end of the session."

Clinical • Acne Vulgaris

Beyond Active Ingredients: The Impact of Control Arms in Dermatology (EADV 2024) - " Acne: Two identical, large-scale, 12-week, double-blinded, randomised, multicentre, and vehicle-controlled phase 3 studies (n = 1,524 and n = 1,293) demonstrated that once-daily application of trifarotene 50 μ g/g cream significantly improved both facial and truncal acne, with success rates of up to 42.3% and 42.6%, and reduced mean inflammatory lesions by up to 66.2% and 65.4%, respectively (p < 0.001 for all factors)...Rosacea: Two identical, large-scale, 12-week, double-blinded, randomised, multicentre, and vehicle-controlled phase 3 studies (n = 683 and n = 688) showed effectiveness of once-daily application of ivermectin 1% cream in reducing rosacea symptoms, with success rates reaching 38.4% and median inflammatory lesion reduction reaching 76.0% (p < 0.001 for both)...Melasma: A 40-week, randomised, and vehicle-controlled trial (n = 30) showed that twice-daily application of isotretinoin 0.05% gel insignificantly reduced melasma severity and melanin..."

Acne Vulgaris • Actinic Keratosis • Dermatology • Dermatopathology • Rosacea

Phase 4 analyses: Trifarotene reduces atrophic acne scars across all skin types with greater effect in subjects with higher baseline acne and acne scarring severity (EADV 2024) - "Trifarotene was efficacious in reducing acne scars across subgroups examined with a much higher treatment effect in subjects with more severe acne and/or acne scarring."

Clinical • P4 data • Acne Vulgaris • Dermatology

Unlocking the patient perspective: Exploring acne-induced hyperpigmentation in the Phase 4 LEAP study (EADV 2024) - "Although the LEAP study clinical endpoints did not reach statistical significance at Week 24, the study provided valuable insight into the effect of trifarotene on AIH. These exit interviews offer a deeper understanding of the burden of AIH, perceived changes, and treatment satisfaction from the patient ’ s perspective. The results provide evidence for trifarotene as a potential treatment option to help improve AIH and its associated impact."

Clinical • P4 data • Acne Vulgaris

Phase 4 Analyses: Trifarotene Reduces Atrophic Acne Scars Across All Skin Types With Greater Effect in Subjects with Higher Baseline Acne and Acne Scarring Severity (EADV 2024) - "Trifarotene was efficacious in reducing acne scars across subgroups examined with a much higher treatment effect in subjects with more severe acne and/or acne scarring."

Clinical • P4 data • Acne Vulgaris

Trifarotene alleviates skin photoaging injury by inhibition of JNK/c-Jun/MMPs. (PubMed, Acta Pharm) - "Concentrations of malondialdehyde, tyrosinase, interleukin-6, interleukin- 12, and tumor necrosis factor-alpha in photoaged skin decreased, while SOD content in photodamaged HaCaT cells significantly increased. Trifarotene (3.3 μmol L-1) inhibited phosphorylated JNK and c-Jun expression both independently and collaboratively with the JNK activator anisomycin, demonstrating that trifarotene mitigates UV-induced collagen degradation and apoptosis through inhibition of the JNK/c-Jun/MMPs signaling pathway."

Journal • Oncology • IL6 • TNFA • Tyrosinase

Role of Trifarotene in the Management of Acne in Indian Patients: Insights From an Indian Dermatology Experts' Meeting. (PubMed, Cureus) - "Trifarotene emerges as a promising therapeutic option but challenges remain, particularly in optimizing ancillary care to minimize treatment-related adverse effects. Addressing these issues will enhance treatment outcomes and patient satisfaction in acne management, emphasizing the importance of tailored approaches in clinical practice."

Journal • Review • Acne Vulgaris • Dermatology

An Overview on the Management of Atrophic Acne Scars: The Role of Trifarotene as an Adjunct. (PubMed, Skin Therapy Lett) - "Recently, data on trifarotene supports its application in acne scarring. Herein, we provide a succinct review on various treatments for acne scarring and explore how trifarotene and its mechanism of action present an additional topical approach to target atrophic acne scarring."

Journal • Review • Acne Vulgaris • Dermatology • Inflammation

Exploring the role of trifarotene against RAR-α: an investigation of expression pattern and clinicopathological significance of RAR-α in breast cancer. (PubMed, Front Pharmacol) - "Overall, this research indicates that elevated expression of RAR-α enhances the onset of breast cancer. Using trifarotene medication to target RAR-α will significantly boost the response of breast cancer individuals to treatment and delay the development of resistance to drugs."

Journal • Brain Cancer • Breast Cancer • CNS Tumor • Glioma • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pediatrics • Solid Tumor

Nilotinib-induced generalized keratosis pilaris (EADV-Sp 2024) - "Due to the patient’s high concern for this widespread skin reaction, nilotinib was discontinued and topical keratolytic including urea cream and topical retinoid trifarotene were applied. After 1 month, his skin lesion showed complete resolution and imatinib (first-generation Bcr-Abl TKI) treatment was started, without any cutaneous adverse reaction. We present a rare but interesting case of generalized keratosis pilaris induced by nilotinib. Clinicians need to be aware of this potential cutaneous adverse reaction induced by nilotinib."

Alopecia • Chronic Myeloid Leukemia • Dermatology • Hematological Malignancies • Immunology • Leukemia • Oncology • Pruritus • ABL1 • BCR

Comparison of the Efficacy of Clascoterone, Trifarotene, and Tazarotene for the Treatment of Acne: A Systematic Literature Review and Meta-Analysis. (PubMed, Dermatol Ther (Heidelb)) - "No significant differences in efficacy were observed between clascoterone, trifarotene, and tazarotene after 12 weeks of treatment in patients with moderate-to-severe acne. Differences in application frequency and safety profile should also be taken into consideration when making treatment decisions."

Journal • Retrospective data • Review • Acne Vulgaris • Dermatology

Editor's Highlights - June 2024. (PubMed, Int J Dermatol) - "Recent studies focusing on trifarotene, a selective retinoic acid receptor gamma agonist, demonstrated significant improvements in acne severity and postinflammatory hyperpigmentation in SOC patients. We will also delve into the early and aggressive treatment of HS and highlight a link between HS and increased cardiovascular risk. These insights demand a paradigm shift toward a more proactive and holistic management of HS, integrating skin and systemic health considerations to enhance patient outcomes significantly."

Journal • Acne Vulgaris • Cardiovascular • Dermatology • Hidradenitis Suppurativa • Immunology • RARG

Trifarotene-based holistic management of acne. (PubMed, Int J Dermatol) - No abstract available

Journal • Acne Vulgaris

Importance of treating acne sequelae in skin of color: 6-month phase IV study of trifarotene with an appropriate skincare routine including UV protection in acne-induced post-inflammatory hyperpigmentation. (PubMed, Int J Dermatol) - "In all skin phototypes, there was more rapid improvement in the ODS and PAHPI scores with trifarotene by Weeks 12 and 24, respectively. The combination of trifarotene and skincare correlated with high patient satisfaction and adherence to the treatment protocol."

Journal • P4 data • Acne Vulgaris • Dermatitis • Dermatology • Inflammation